2.44
-0.38(-13.48%)
Currency In USD
| Previous Close | 2.82 |
| Open | 2.78 |
| Day High | 2.86 |
| Day Low | 2.2 |
| 52-Week High | 108 |
| 52-Week Low | 2.2 |
| Volume | 273,181 |
| Average Volume | 229,018 |
| Market Cap | 1.24M |
| PE | -0.1 |
| EPS | -23.7 |
| Moving Average 50 Days | 4.2 |
| Moving Average 200 Days | 11.49 |
| Change | -0.38 |
If you invested $1000 in Salarius Pharmaceuticals, Inc. (SLRX) 10 years ago, it would be worth $0 as of November 10, 2025 at a share price of $2.44. Whereas If you bought $1000 worth of Salarius Pharmaceuticals, Inc. (SLRX) shares 5 years ago, it would be worth $1.09 as of November 10, 2025 at a share price of $2.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
GlobeNewswire Inc.
Oct 13, 2025 12:45 PM GMT
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained complia
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire Inc.
Sep 09, 2025 12:00 PM GMT
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
GlobeNewswire Inc.
Aug 14, 2025 12:30 PM GMT
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment